SANUWAVE Health posted second quarter 2026 revenue that exceeded revised guidance but slightly declined year-over-year, reflecting gradual commercial gains in shockwave therapy devices amid challenging reimbursement dynamics. The company’s ongoing financial restatement related to state sales and use tax liabilities signals past accounting issues but appears contained, as liquidity remains adequate. SANUWAVE’s market position depends heavily on healthcare provider adoption of its wound healing technology, regulatory approvals, and reimbursement coverage, with cybersecurity vulnerabilities posing operational risks. Close monitoring of device sales momentum and regulatory milestones will be critical for assessing the sustainability of growth.